Princess Private Equity Holding (PGPE) reported an 8.6% decline in net asset value (NAV) for the first half of 2026, as portfolio-level performance over the prior 12 months to June 2026 fell 8.3%. The company returned nearly EUR 36 million to shareholders during the period, including EUR 22 million via its first interim dividend and EUR 13 million through buybacks, with an additional EUR 5 million deployed post-period.
Total distributions received amounted to approximately EUR 111 million, equivalent to about 14% of net assets, while new investments deployed totaled EUR 13 million. The firm maintained EUR 51 million in cash and cash equivalents and retained a fully undrawn EUR 150 million revolving credit facility.
EBITDA growth among the top 20 portfolio companies slowed to 4.5% over the last 12 months, down from historical ranges of 13% to 15% annually. Management described the current growth rate as "a low point" and projected a rebound toward historical levels by 2027.
PGPE’s shares rose 1.3% to $7.50, following a 27.8% year-to-date total return and an 18.8% gain over the past six months. The stock is trading 31% below its 52-week high of $10.90 and roughly 10% above its low of $6.80, with a market capitalization of $1.1 billion. The prospective dividend yield exceeds 8% at the current share price, while the trailing yield stands at 4.43%.
Portfolio monetizations included the sale of Clario to Thermo Fisher Scientific for over $9 billion, generating EUR 23 million for PGPE at a near 3x multiple on invested capital. Galderma was fully realized via a full sell-down, delivering a money multiple above 3.5x, while Vishal Mega Mart was monetized for over EUR 15 million at a multiple above 8.5x with a distributed-to-paid-in (DPI) ratio near 5x.
Pre-2021 vintage assets have seen approximately 80% of invested capital fully realized, achieving a 2.7x multiple, with remaining assets marked just below 2x on a blended basis. Younger companies, representing just over 20% of NAV, posted a blended internal rate of return near 20%.
Artificial intelligence adoption across the portfolio reached about 90%, with documented EBITDA benefits of EUR 10 million and a 120-basis-point margin improvement in one case study. Management expects AI initiatives to unlock EUR 170 million in visible EBITDA opportunities by 2027.
The company plans to submit a circular and prospectus to shareholders in early September regarding a proposed dual share class structure.
